Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Has results × selinexor × Clear all

Phase

Phase 2 17 Phase 1/2 7 Phase 1 7 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Magnetic Resonance Spectroscopy 7 Cyclophosphamide 7 Paclitaxel 6 Leucovorin 6 Granulocyte Colony-Stimulating Factor 6 Filgrastim 6 Etoposide 6 Drug Therapy 6 Cisplatin 6 Oxaliplatin 5 Nivolumab 5 Fluorouracil 5 Doxorubicin 5 Carboplatin 5 Bevacizumab 5 Sirolimus 4 Rituximab 4 Radiotherapy, Intensity-Modulated 4 Radiotherapy 4 Melphalan 4 Immunoglobulin G 4 Gemcitabine 4 Docetaxel 4 Disulfides 4 Cytarabine 4 Capecitabine 4 pembrolizumab 3 gallium 68 PSMA-11 3 dexamethasone acetate 3 dexamethasone 21-phosphate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡